Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?

@article{Hunstein2007Epigallocathechin3gallateIA,
  title={Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?},
  author={Werner Hunstein},
  journal={Blood},
  year={2007},
  volume={110 6},
  pages={
          2216
        }
}
To the editor: This unusual letter comes from Heidelberg, where the first description of amyloidosis was published in 1859.[1][1] The first autologous transplantation of blood-derived hematopoietic stem cells was conducted here in 1985 in my university hospital department and reported in Blood in 

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Light chain amyloidosis 2012: a new era.

  • British journal of haematology
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Light Chain Amyloidosis

  • Mediterranean journal of hematology and infectious diseases
  • 2018

Novel Therapies in Light Chain Amyloidosis

  • Kidney international reports
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-3 OF 3 REFERENCES

Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma

M Körbling, B Dörken, +3 authors TM. Fliedner
  • 1986

Zur Amyloidfrage

AL Wurster, SL Reiner, MJ Grusby, N Friedreich, A. Kekulé
  • Virchows Arch Path Anat Klin Med .
  • 1859